Trazodone is not approved by the FDA for pain relief, but it is sometimes prescribed off-label for chronic pain conditions, particularly fibromyalgia, neuropathic pain, and chronic facial pain disorders. Its primary approved use is treating major depressive disorder in adults. When doctors do prescribe it for pain, the benefit often comes indirectly through improved sleep and reduced pain interference with daily life rather than through a dramatic drop in pain intensity itself.
Why Doctors Sometimes Prescribe It for Pain
Trazodone occupies an unusual position among antidepressants. While several antidepressants have established roles in pain management (tricyclic antidepressants for nerve pain, for example), trazodone’s path into pain treatment has been less straightforward. It tends to show up in treatment plans for patients who have chronic pain combined with poor sleep, since disrupted sleep amplifies pain perception and trazodone is widely used as a sleep aid.
The conditions where trazodone appears most often in pain-related prescribing include fibromyalgia, painful diabetic neuropathy, and temporomandibular disorders (chronic jaw and facial pain). In all three cases, sleep disruption is a core feature of the condition, which makes trazodone a logical choice for clinicians trying to address multiple symptoms with a single medication.
How It Affects Pain Signaling
Animal research has identified two main pathways through which trazodone reduces pain sensitivity. The first involves the body’s own opioid system. In mice, trazodone’s pain-relieving effect was significantly blocked when researchers used drugs that shut down opioid receptors, specifically the mu-opioid receptor subtypes that are central to how the body naturally dampens pain signals. The second pathway involves serotonin. When researchers blocked serotonin receptors, trazodone’s analgesic effect also decreased. Blocking the adrenaline-related receptors, by contrast, made no difference.
This dual mechanism (engaging both natural opioid pathways and serotonin signaling) sets trazodone apart from many other antidepressants used for pain, which typically work through serotonin and norepinephrine reuptake alone. It also helps explain an observation from clinical practice: trazodone appears to have opioid-sparing effects, meaning patients using it for chronic pain may need lower doses of actual opioid medications.
What the Fibromyalgia Evidence Shows
The most detailed clinical data on trazodone for pain comes from a 12-week open-label study of 66 fibromyalgia patients taking flexible doses between 50 and 300 mg per day. The results painted a nuanced picture. Sleep quality improved dramatically, with large effect sizes across total sleep scores, sleep duration, and sleep efficiency. Fatigue, morning tiredness, stiffness, and anxiety all showed moderate to large improvements by week 12.
Pain intensity itself, however, did not markedly improve. What did change was how much pain interfered with daily activities, which reached statistical significance by the end of the study. This distinction matters. For someone with fibromyalgia, sleeping better and functioning more normally during the day can be transformative even if the raw pain level on a 0-to-10 scale doesn’t shift much. But if you’re looking for a medication that directly reduces pain scores the way a traditional painkiller would, trazodone is probably not that drug.
Neuropathic Pain Research
For nerve pain specifically, the evidence is thinner. A randomized, double-blind, placebo-controlled trial enrolled 142 patients with painful diabetic neuropathy to test low doses of trazodone (30 mg or 60 mg daily) over eight weeks. Notably, all patients in the trial also received gabapentin, a standard nerve pain medication, so the study was designed to test whether adding trazodone on top of existing treatment provided extra benefit. Results from this trial have not been published, leaving a gap in the evidence for this specific use.
A separate clinical trial examining trazodone for temporomandibular disorder pain (a chronic condition affecting the jaw joint) was terminated before completion, which means that data set is also incomplete. The pattern across the research landscape is consistent: trazodone is being investigated for multiple pain conditions, but robust, completed trial data remains limited.
Doses Used for Pain vs. Depression
For depression, trazodone typically starts at 150 mg per day in divided doses, with a maximum of 400 mg daily for outpatients. When prescribed off-label for pain conditions, doctors generally use lower doses. The diabetic neuropathy trial tested just 30 to 60 mg per day, and the fibromyalgia study allowed doses from 50 to 300 mg. In practice, many patients receiving trazodone primarily for sleep improvement in the context of a pain condition take doses at the lower end of this range, often 50 to 150 mg at bedtime.
Side Effects to Be Aware Of
Trazodone is generally considered to have a milder side-effect profile than tricyclic antidepressants, which are more commonly prescribed for chronic pain. Drowsiness is the most predictable effect, which is why the medication is almost always taken at bedtime. Dizziness upon standing (from a drop in blood pressure) is another common issue.
One finding from the fibromyalgia study was unexpected: 21% of patients reported tachycardia (a noticeably fast heartbeat), making it the most frequent and severe side effect in that group. This rate was higher than typically reported in depression studies, though whether fibromyalgia patients are uniquely susceptible or this was a quirk of the sample remains unclear. Overall, no deaths have been reported from trazodone overdose, which gives it a notable safety advantage over tricyclic antidepressants, where overdose can be fatal.
How It Compares to Other Antidepressants for Pain
Tricyclic antidepressants like amitriptyline remain the most established antidepressant class for chronic pain, with decades of evidence supporting their use in nerve pain, fibromyalgia, and chronic headaches. Trazodone does not have that depth of evidence. Its advantages are practical: fewer anticholinergic side effects (dry mouth, constipation, urinary retention), a better safety profile in overdose, and strong sleep-promoting effects that can be valuable when insomnia is part of the pain picture.
The opioid-sparing property is another potential advantage. For patients managing chronic pain with opioid medications, adding trazodone may allow for lower opioid doses, reducing the risk of dependence and other opioid-related complications. This benefit, while noted in clinical summaries, still lacks the kind of large-scale trial data that would make it a standard recommendation.
If you’re considering trazodone specifically for pain, the honest summary is this: it works best as a supporting player rather than a lead actor. Its strongest effects are on sleep and daily functioning, which in turn can make pain more manageable. Direct pain relief, based on current evidence, is modest at best.